Ocular Oncology News

A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.

CARLSBAD, Calif. — Patients with uveal melanoma who had Medicaid or no insurance were less likely to receive brachytherapy and more likely to be diagnosed at later stages, according to a study presented here.

A 45-year-old woman with a medical history of breast cancer status post mastectomy presented to Lahey Eye Clinic due to 2 weeks of blurry vision, described as a “haze over her eyes.”

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, highlights the important takeaways from International Symposium on Pediatric Neuro-Oncology.

PHILADELPHIA — In this video, Michael Fisher, MD, discusses the results of a natural history study he presented at the International Symposium on Pediatric Neuro-Oncology.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura Biosciences discusses a phase 3 program in ocular oncology.

WAILEA, Hawaii — The world of melanoma has changed a lot in recent years and more change is yet to come, according to a speaker at Hawaiian Eye 2024.

The top Healio ocular oncology-related articles in 2023 explored telemedicine’s growing promise and barriers, as well as risk features for malignant melanoma transformation in the eye.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial assessing belzupacap sarotalocan, according to a press release.